ALK and non-small cell lung carcinoma: Small-cell lung cancer accounts for about 10–15% of global incidence, while non-small-cell lung cancers (NSCLCs) account for the majority, with subsets of patients showing mutations in various genes, including Epidermal growth factor receptor (EGFR), Anaplastic lymphoma kinase (ALK), ROS1, and Neurotrophin receptor kinase (NTRK).